Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19588665 | 0.98 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL128692 | 0.98 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL20067101 | 0.98 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL20077560 | 0.98 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL27367847 | 0.98 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL31373110 | 0.96 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL31296126 | 0.96 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL30454549 | 0.96 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL30985685 | 0.96 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| Bromide SCHEMBL28905083 | 0.96 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | BHATTACHARYA SHRABANTI (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| EP-4463456-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BeiGene, Ltd. (KY) | 2024-11-20 | — | — | EP | disclosed |
| EP-2416392-A2 | Light emitting device and display unit | Ricoh Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110077418-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | CHEMINOVA A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| WO-2010094164-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | CHEMINOVA A/S (DK) | 2010-08-26 | — | — | WO | disclosed |
| US-20090036713-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | EVONIK DEGUSSA GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1991520-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | Evonik Degussa GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007101769-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | EVONIK DEGUSSA GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213540-A1 | Process for the hydrogenation of imines | DEGUSSA AG (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077418-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | INTS9, INTS6, INF2 | EPHX2 1443/4885HSD11B1 43/4885KMT2A 3700/4885 |
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | CA4, CA12, CA14 | EPHX2 1537/4885HSD11B1 1341/4885KMT2A 229/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | EPHX2 434/4885HSD11B1 1493/4885KMT2A 38/4885 |
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | EPHX2 3334/4885HSD11B1 2464/4885KMT2A 2166/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | EPHX2 3201/4885HSD11B1 4668/4885KMT2A 3318/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | EPHX2 3203/4885HSD11B1 4671/4885KMT2A 3301/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX2 3893/4885HSD11B1 2525/4885KMT2A 4093/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX2 3893/4885HSD11B1 2525/4885KMT2A 4093/4885 |
| US-20090036713-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | IPO5, IPO4, HRH3 | EPHX2 1832/4885HSD11B1 1121/4885KMT2A 869/4885 |
| US-20070213540-A1 | Process for the hydrogenation of imines | KCNH3, KCNH2, KMO | EPHX2 1484/4885HSD11B1 3302/4885KMT2A 318/4885 |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | EPHX2 3638/4885HSD11B1 1356/4885KMT2A 849/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | EPHX2 3201/4885HSD11B1 4668/4885KMT2A 3318/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX2 3893/4885HSD11B1 2525/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.